Last updated: May 8, 2024
Sponsor: Radboud University Medical Center
Overall Status: Active - Not Recruiting
Phase
N/A
Condition
Vascular Diseases
Circulation Disorders
Parkinson's Disease
Treatment
Head-up tilt sleeping
Clinical Study ID
NCT05551377
NL.80610.091.22
MJFF-020200
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Orthostatic hypotension defined as a systolic BP decrease of ≥20 mmHg, or a diastolicdecrease of ≥10 mmHg, within 3 min after changing from a supine to standing positionOR mean standing BP of ≤75 mmHg (marker for symptomatic orthostatic hypotension). Inpatients with supine hypertension, a decrease in systolic BP of ≥ 30 mmHg is required;
- Orthostatic intolerance: direct complaints (dizziness, blurry vision, etc.) and/orindirect signs (falls or freezing episodes that relate to postural challenge);
- Supine hypertension defined as a systolic BP of ≥140 mmHg, and/or diastolic of ≥90mmHg, after 5 min of supine rest;
- Idiopathic PD or parkinsonism (multiple system atrophy, progressive supranuclearpalsy, corticobasal degeneration, vascular parkinsonism and Lewy body dementia);
- Ability to walk (with or without a walking aid), as subjectively determined by theresearcher;
- Stable medication regimens for orthostatic hypotension and supine hypertension duringthe trial;
Exclusion
Exclusion Criteria:
- Inability to follow instructions and complete questionnaires, as assessed by theresearcher;
Study Design
Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Head-up tilt sleeping
Phase:
Study Start date:
January 18, 2023
Estimated Completion Date:
June 30, 2024
Study Description
Connect with a study center
Radboudumc
Nijmegen, Gelderland 6500 HB
NetherlandsSite Not Available
Leiden University Medical Center
Leiden, Zuid Holland 2333 ZA
NetherlandsSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.